Chinese
Japan
English
ProBio Announces New Executive Appointments - ProBio
GenScript Subsidiary ProBio Instrumental in Latest Fight Against Cancer - ProBio
ProBio Accelerates Chimagen’s Global Market Expansion, Paving the Way for Innovative Antibody Therapy - ProBio
ProBio and UCI Therapeutics Sign a Strategic Cooperation MOU for Comprehensive Collaboration in Gene Delivery Technologies, Including Viral and Non-Viral Approaches - ProBio
ProBio Extends Congratulations to InnoBation Bio on MFDS Clearance of IBC101 Program - ProBio
ProBio Signs Collaboration Agreement with Cell Resources Corporation, a Subsidiary of Alfresa Holdings Corporation for Cell Therapy Development - ProBio
ProBio announces the appointment of Dr. Li Chen, as the Chief Executive Officer - ProBio
ProBio Congratulates TG ImmunoPharma on FDA Clearance of Clinical Trial for TGI-5 Monoclonal Antibody - ProBio
ProBio signs viral vector manufacturing MOU with Curocell for next-generation CAR-T therapy - ProBio
The MOU between ProBio and NuclixBio - ProBio
ProBio Partners with Epi Biotech to Advance Hair Loss Antibody Therapy - ProBio
ProBio Congratulates ABL Bio’s IND Clearance of ABL103 Program from MFDS - ProBio
Dx&Vx Signs Strategic Partnership with ProBio for Novel Drug Development - ProBio
ProBio Congratulates IMBiologics on FDA Clearance of IND Application for Innovative Bispecific Antibody Drug Project (IMB-101) - ProBio
ProBio and Comprehensive Cell Solutions, a Business Unit of the New York Blood Center Enterprises, Form a Pioneering Partnership to Expedite Cell and Gene Therapy Development and Manufacturing - ProBio
ProBio Congratulates Eutilex’s IND Clearance from MFDS - ProBio
ProBio and RVAC Medicines Announce Strategic Partnership for GMP Plasmid DNA Manufacturing for mRNA COVID-19 Vaccine Candidate - ProBio
A Joint Collaboration Between Bio Immunitas and ProBio Leads to the Development and Fast Track Manufacturing of A Novel Therapeutic Platform - ProBio
ProBio Congratulates Selecxine’s IND Clearance from MFDS - ProBio
Program CD47, provided the CMC service by ProBio to InnobationBio, will further be advanced by the joint venture between Liminatus Pharma LLC and Iris Acquisition Corp - ProBio